A history lesson

Debates on the legitimacy of a diagnosis of attention deficit hyperactivity disorder (ADHD) in children or adults are still raging1 2 because of a lack of understanding of the history of the disorder. Drug companies have indeed marketed the concept of adult ADHD to potential consumers1—as they did childhood ADHD to parent-teacher associations in the United States during the 1960s and 1970s—but this is only part of the story. Disorders such as ADHD reflect the disconnection between society’s expectations for the academic and occupational performance of children and adults and their ability to live up to such expectations.

My research shows that ADHD as we know it emerged in the United States during the 1950s, when a lot was expected of the baby boom generation, the first hyperactive children and the largest cohort ever born in the US. Concerned about perceived American deficiencies in science and technology, as evidenced by the Soviet launching of Sputnik, education critics demanded more of students, thus giving rise to the phenomenon of hyperactivity but also depression, psychosis, and anxiety. One of these drugs, which had previously been marketed to geriatric and depressed patients as a “pep pill,” was methylphenidate (Ritalin).

The history of psychiatric concepts needs to be understood to deal with them effectively and move away from polarised debates that lead nowhere.

Matthew P C Smith
Wellcome Trust research fellow, Centre for Medical History, University of Exeter, Armary Building, Exeter EX4 4RF m.p.c.smith@ex.ac.uk

Competing interests: None declared.

Cite this as: BMJ 2010;340:c2241

CANNABIS USE DISORDERS

Helping the youngest users

Winstock and colleagues’ review of cannabis use disorders in primary care emphasises that the youngest users are at the greatest risk of harm1—for example, a depressed pregnant adolescent in local authority care. Long term anxiety is common among young people who smoke this drug. Symptoms such as panic and paranoia can emerge abruptly. Doctors often struggle to engage with school age users.

The review seems oriented to general practice surgeries.1 Excellent advice is available from the Royal College of General Practitioners’ Adolescent Primary Care Society. However, case identification (the teachable moment for a young person) is more likely to arise in school health care. In schools, “you’re welcome” skills to build trust between clinician and teenager are crucial.2 Unprecedented levels of emotional distress are now developing by the age of 15,3 so establishing trust is more important than ever—before talking about illicit drugs.

Adolescent cannabis use appears in many other community services yet referrals for clinical management are rare. How can we improve health care for young users? Most have families, and family intervention
projects and parenting early intervention programmes are spreading. Appropriate whole family assessments should include a clinical assessment of the impact of smoking cannabis on children in the family, including use by siblings and carers. For that most vulnerable pregnant teenager in local authority care mentioned above, the Children Act 2004 promised a lead professional. Her local authority has a duty to ensure registration with a general practitioner. That general practitioner needs to collaborate with her lead professional—and with her.

Woody Caan, professor of public health, Department of Child and Family Health, Anglia Ruskin University, Cambridge CB1 1PT; woody.caan@anglia.ac.uk

Competing interests: None declared.

1 Winstock AR, Ford C, Witton J. Assessment and management of cannabis use disorders in primary care. *BMJ* 2010;340:c1571. (1 April.)

Cite this as: *BMJ* 2010;340:c2242

**NHS COMMISSIONING SYSTEM**

No data, no commissioning

A parliamentary advisory committee has rightly found that commissioning by primary care trusts is adding little, if anything, to the NHS. 

Regardless of the quality of management, data on much trust spending are lacking. Even when the cost of acute hospital care is known, clinical thresholds are not, and trusts seem to have little idea of whether their patients are getting care at above or below the national rate. Outside of acute hospital care, trusts have almost no idea of costs and none of outcomes. With so few data, how can they commission effectively?

Without a major investment in more and better data at primary care trust level, commissioning will inevitably be ineffective. The government quotes examples of trusts having made a difference, but scrutiny is likely to show that they are rare, entail small sums of money, are mainly the result of local enthusiasm, and lack a clear evidence base. That is certainly my experience of looking at projects that have come under the spotlight. Why are only two or three economists working in primary care trusts? Because there are no data for them to work with.

Peter A West, semi-retired consulting health economist, London SW20 0LP; p.a.west@blueyonder.co.uk

Competing interests: PAW is a health economist and has worked for primary care trusts, many other parts of the NHS, the Department of Health, and the private sector.

1 O’Dowd A. Entire NHS commissioning system may need to be scrapped, MPs say. *BMJ* 2010;340:c1792. (30 March.)

Cite this as: *BMJ* 2010;340:c2134

**What took so long?**

GP fundholding seemed to make a difference, but many would argue that it came at a high cost. Little else has come out of the purchaser-provider split. The big moves forward like stroke services and cardiac networks have happened through collaboration between providers and commissioners, or through central targets. Primary care trusts, however, have a huge self interest in keeping the farce of locality commissioning, practice based commissioning, world class commissioning, etc, going. Who will have the courage to stop it and face the redundancies and loss of face that will ensue? Locally our main achievement has been to send patients home after cataract operations with two bottles of eye drops instead of one, and that took a year to achieve.

Nicholas J Sharville, general practitioner, Deal, Kent CT14 7EQ; john.sharville@nhs.net

Competing interests: None declared.

1 O’Dowd A. Entire NHS commissioning system may need to be scrapped, MPs say. *BMJ* 2010;340:c1792. (30 March.)

Cite this as: *BMJ* 2010;340:c2136

**OPEN ACCESS PUBLISHING**

And now, e-publication bias

In open access publishing scholarly communication is made available free of charge on the internet. In biomedical research, authors or sponsors often pay a fee to a publisher to enable immediate free online access. A few journals operate entirely under this model, whereas others use a hybrid model allowing authors to choose between subscription access and author-paid open access.

We investigated the association between funding of biomedical research by industry and author-paid open access publishing in the *Annals of the Rheumatic Diseases*, a journal in the BMJ Group. We included extended reports published during October 2007 to September 2008, defining primary exposure as study funding from an industrial source with commercial interests in the area studied, and secondary exposure as other author-industry affiliations. Access (the outcome measure) was defined as locked (subscription access) or unlocked (open access). Of 216 extended reports, 71 had received funding from an industrial sponsor. A significantly higher proportion of industry funded studies were published unlocked (12/71 (17%) v 11/145 (8%)) (table).

Studies with at least one author declaring other affiliations with industry also showed a significantly higher frequency of unlocked papers. There was no significant interaction between study design and funding in relation to open access.

Our results show that author-paid open access publishing preferentially increases accessibility to studies funded by industry. This could favour dissemination of pro-industry results. We suggest the term e-publication bias for this emerging type of publication bias in open access hybrid journals, which may be relevant beyond the *Annals of the Rheumatic Diseases* and rheumatology.

Ane Krag Jakobsen MD, Department of Urology, Roskilde University Hospital, 4000 Roskilde, Denmark; anekrag@yahoo.com

Robin Christensen, senior biostatistician, Parker Institute: Musculoskeletal Statistics Unit, Copenhagen, Denmark

Robert Persson MD, Eden Primary Care Unit, Region Skåne, Malmo, Sweden

Else Marie Bartels, senior research librarian, Parker Institute: Musculoskeletal Statistics Unit, Copenhagen, Denmark

Lars Erik Kristensen MD, Department of Clinical Sciences, Lund, Section of Rheumatology, Lund University, Lund, Sweden

Competing interests: RC is editor in the Cochrane Collaboration (Cochrane Musculoskeletal Review Group).

1 Davis PM, Lewenstein BV, Simon DH, Booth JG, Connolly MI. Open access publishing, article downloads, and citations: randomised controlled trial. *BMJ* 2008;337:a568. (31 July.)

Cite this as: *BMJ* 2010;340:c2243

**Effect of primary and secondary exposures and potential confounders on open access status**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Odds ratio (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry funding</td>
<td>2.48 (1.03 to 5.94)</td>
<td>0.037</td>
</tr>
<tr>
<td>Employment</td>
<td>4.02 (1.62 to 9.98)</td>
<td>0.002</td>
</tr>
<tr>
<td>Equity</td>
<td>7.22 (2.29 to 22.70)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Other grants</td>
<td>12.73 (4.57 to 35.46)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Fees to individual researchers</td>
<td>16.78 (5.95 to 47.30)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Randomised controlled trials</td>
<td>2.92 (0.86 to 9.84)</td>
<td>0.073</td>
</tr>
</tbody>
</table>

No of authors* | 1.65 (0.82 to 3.34) | 0.163 |

*In univariate logistic regression model.